COMPARE · Data as of August 21, 2026
HALO vs HRMY
Verdict: Side-by-side breakdown using the Bull Rankings model. HALO scored 79.5, HRMY scored 88.7 — HRMY leads.
Compare another set
HALO
Halozyme Therapeutics, Inc.
79.5
$106.12 · $12.0B
fundamentals as of
Score gap
9.2
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
88.7
$38.07 · $2.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHRMY12.3x
- Fastest growthHALO+41.2%
- Highest qualityHALO96 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
HALO
stronger →← stronger
HRMY
96
Qualityreturns · margins · balance sheet
80
97
Growthrevenue & earnings expansion
91
54
Valuevaluation vs sector peers
95
HALO is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
HALO
HRMY
$806mC+
FCF
$355mC
+41.2%A
Rev
+24.3%A-
—
D/E
0.16B+
31.1xB
P/E
12.3xA
1.47B
PEG
0.44A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HALO
HRMY
40% below
Price vs fair valuelower is cheaper
75% below
~0%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-18%/yr
+32%
1-yr DCF upside
+207%
+66%
5-yr DCF upside
+304%
+133%
10-yr DCF upside
+507%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HALO
Why this score
- Buying back stock
- Durable high returns
HRMY
Why this score
- Durable high returns
The companies
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.0b. Trading near 52-week high of $107.96 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -6% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 31x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 7% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +21% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
HRMY leads The Bull Rankings with a 90.7 score, primarily due to its superior Value pillar of 93, significantly outpacing HALO's 67 and its P/E grade of A (12.4x). A contrarian could still prefer HALO for its robust revenue growth of +41.2% (grade A), which is considerably higher than HRMY's +24.3%.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HALO and HRMY diverge
On the headline score the gap is 9.2 points in favor of HRMY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueHALO 54.1 · HRMY 95.4HRMY +41.3
- QualityHALO 95.7 · HRMY 79.9HALO +15.8
- GrowthHALO 97.0 · HRMY 91.5HALO +5.5
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.